-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, HUTCHMED Reports Phase III SACHI Trial Published In The Lancet Demonstrating Improved PFS With Savolitinib Plus Osimertinib Versus Chemotherapy

Benzinga·01/14/2026 07:19:11
Listen to the news
  • First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment.
  • Savolitinib and osimertinib combination approved in China in June 2025.